Vasomedical

Vasomedical is engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP® ) therapy systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system diseases that is cleared by the FDA and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance, and a staff training and maintenance programs designed to provide optimal patient outcomes. The Company also provides other non-invasive medical equipment including a full range of Biox™ ECG Holter monitors recorders and ambulatory blood pressure monitors.
Company Growth (employees)
Type
Public
HQ
Plainview, US
Founded
1994
Size (employees)
218 (est)
Vasomedical was founded in 1994 and is headquartered in Plainview, US

Vasomedical Office Locations

Vasomedical has offices in Plainview and New York
Plainview, US (HQ)
200 137 Commercial St
New York, US
1702 111 John St

Vasomedical Data and Metrics

Vasomedical Financial Metrics

Vasomedical's revenue was reported to be $16.4 m in Q1, 2017
USD

Revenue (Q1, 2017)

16.4 m

Gross profit (Q1, 2017)

9.1 m

Gross profit margin (Q1, 2017), %

55%

Net income (Q1, 2017)

(2.1 m)

EBIT (Q1, 2017)

(1.8 m)

Market capitalization (20-Jul-2017)

12.8 m

Closing share price (20-Jul-2017)

0.1

Cash (31-Mar-2017)

6.7 m
Vasomedical's current market capitalization is $12.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

32.9 m35 m57.1 m72.6 m

Revenue growth, %

6%63%27%

Cost of goods sold

10.4 m9.8 m21.7 m31.1 m

Gross profit

22.5 m25.2 m35.4 m41.5 m

Gross profit Margin, %

68%72%62%57%

R&D expense

530 k

General and administrative expense

39.4 m

Operating expense total

23.8 m24.1 m31.4 m39.9 m

EBIT

(1.3 m)1.1 m3.9 m1.6 m

EBIT margin, %

(4%)3%7%2%

Interest income

87 k207 k312 k187 k

Pre tax profit

(1.2 m)1.3 m3.8 m1.1 m

Income tax expense

58 k(127 k)44 k(281 k)

Net Income

(1.1 m)1.1 m3.8 m820 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

7.9 m7.6 m7.5 m10.8 m17.4 m17.5 m18.2 m17.5 m16.4 m

Cost of goods sold

2.4 m2.3 m1.9 m3.5 m7.6 m7.5 m8.1 m7.4 m7.3 m

Gross profit

5.5 m5.4 m5.6 m7.3 m9.9 m10 m10.1 m10.2 m9.1 m

Gross profit Margin, %

70%70%75%68%57%57%56%58%55%

Sales and marketing expense

6.7 m6.4 m6.4 m

R&D expense

206 k180 k134 k137 k158 k147 k105 k117 k221 k

General and administrative expense

5.5 m5.3 m5.7 m7 m8.4 m9.7 m9.7 m9.5 m10.7 m

Operating expense total

12.4 m11.9 m12.2 m7.1 m8.5 m9.9 m9.8 m9.6 m10.9 m

EBIT

(206 k)(149 k)(286 k)206 k1.3 m159 k264 k502 k(1.8 m)

EBIT margin, %

(3%)(2%)(4%)2%8%1%1%3%(11%)

Interest income

44 k52 k40 k80 k79 k10 k68 k104 k(12 k)

Pre tax profit

(162 k)(97 k)(246 k)197 k1.3 m(2 k)162 k431 k(2 m)

Income tax expense

(14 k)(26 k)(6 k)(6 k)(38 k)(102 k)51 k(103 k)(109 k)

Net Income

(176 k)(123 k)(252 k)191 k1.2 m(104 k)213 k328 k(2.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

8 m9.1 m2.2 m7.1 m

Inventories

363 k512 k2.4 m

Current Assets

25.9 m29 m18.8 m25.1 m

Goodwill

3.3 m3.3 m17.5 m17.3 m

Total Assets

33.5 m41 m50.4 m57.4 m

Accounts Payable

597 k462 k4 m5.2 m

Total Debt

326 k9.8 m

Current Liabilities

19.2 m19.8 m22.5 m25.7 m

Non-Current Liabilities

7.8 m13.5 m16.2 m18.8 m

Total Liabilities

27.1 m33.2 m38.7 m

Additional Paid-in Capital

61.5 m61.9 m62.3 m62.9 m

Retained Earnings

(53.6 m)(52.4 m)(48.6 m)(47.8 m)

Total Equity

6.5 m7.8 m11.7 m12.9 m

Debt to Equity Ratio

0 x0.8 x

Debt to Assets Ratio

0 x0.2 x

Financial Leverage

5.2 x5.3 x4.3 x4.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

10 m9.1 m15.3 m2.9 m1.9 m4.7 m5.6 m5.7 m6.7 m

Inventories

1.9 m1.9 m2.1 m2.2 m2 m2.3 m1.7 m2.1 m2.5 m

Current Assets

22.4 m21.2 m25.5 m14.5 m15.9 m18.3 m19 m19.9 m21.9 m

Goodwill

3.3 m3.3 m3.3 m22.6 m22.6 m17.5 m17.4 m17.4 m17.3 m

Total Assets

31.2 m32.3 m36.3 m46.3 m47.4 m49.3 m50.1 m51.9 m54 m

Accounts Payable

480 k525 k567 k3.6 m3.6 m4.1 m4.2 m4.1 m4.2 m

Current Liabilities

16.9 m17.5 m18 m24.8 m24.2 m21.8 m22.7 m21.8 m25.9 m

Non-Current Liabilities

9 m9.7 m10.8 m13.5 m14.1 m15.8 m15.4 m17.5 m17 m

Additional Paid-in Capital

61.8 m61.9 m61.9 m62.2 m62.2 m62.3 m62.5 m62.8 m63.1 m

Retained Earnings

(54.8 m)(54.9 m)(52.7 m)(52.5 m)(51.3 m)(48.7 m)(48.5 m)(48.2 m)(49.9 m)

Total Equity

5.3 m5.2 m7.5 m8 m9.1 m11.7 m12 m12.6 m11 m

Financial Leverage

5.9 x6.2 x4.8 x5.8 x5.2 x4.2 x4.2 x4.1 x4.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(1.1 m)1.1 m3.8 m820 k

Depreciation and Amortization

361 k467 k1.5 m2.2 m

Accounts Payable

255 k(135 k)347 k1.3 m

Cash From Operating Activities

(1.5 m)2.6 m6.5 m5.2 m

Cash From Investing Activities

(228 k)(1.4 m)(18.3 m)(2.3 m)

Cash From Financing Activities

(1.8 m)(46 k)4.7 m1.9 m

Interest Paid

1 k196 k795 k

Income Taxes Paid

69 k48 k130 k549 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(176 k)(123 k)(252 k)191 k1.2 m(104 k)213 k328 k(2.1 m)

Accounts Payable

480 k525 k567 k3.6 m3.6 m4.1 m4.2 m4.1 m4.2 m
USDY, 2017

Revenue/Employee

75.1 k

Financial Leverage

4.9 x

Vasomedical Operating Metrics

FY, 2016

Patents (US)

11

Patents (foreign)

13

Conveyancing Completions

8

Trademarks (foreign)

10

Vasomedical Market Value History

Vasomedical Online and Social Media Presence

Vasomedical Company Life and Culture

You may also be interested in